The National Institute for Health and Care Excellence

Routine NHS access to spinal muscular atrophy treatments offers new hope for patients and families

The decision marks a significant milestone after both medicines were previously made available through managed access agreements while additional evidence on their effectiveness was gathered. SMA is a ...
The National Institute for Health and Care Excellence

Neonatal infection guidance updated to allow home antibiotic treatment for some babies

Some of these babies will need to stay in hospital. But our new guidance says babies born after 35 weeks who are on intravenous antibiotics can be switched to a simple liquid oral antibiotic and taken ...
National Institute for Health and Care Excellence

NICE approves Duchenne muscular dystrophy treatment givinostat after commercial deal sealed

Today’s final draft guidance says givinostat (also called Duvyzat and made by ITF Pharma) can be used to treat Duchenne muscular dystrophy (DMD) in people aged 6 and over who are able to walk or stand ...
National Institute for Health and Care Excellence

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

There is a commercial access agreement for semaglutide. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
The National Institute for Health and Care Excellence

'I no longer feel asthmatic': more than a million people now using new style inhalers

For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...
The National Institute for Health and Care Excellence

NICE announces the appointment of Dr Adrian Hayter as its new chief medical office

NICE today announced the appointment of Dr Adrian Hayter as its new chief medical officer, bolstering the institute’s clinical leadership, following the appointment of CEO Professor Jonathan Benger ...
National Institute for Health and Care Excellence

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...
National Institute for Health and Care Excellence

Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in people 12 years and over. This is because ...
National Institute for Health and Care Excellence

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma

There is a simple discount patient access scheme for glofitamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Suspected sepsis in people aged 16 or over: recognition, assessment and early management

This guideline covers the recognition, diagnosis and early management of suspected sepsis in people aged 16 or over who are not and have not recently been pregnant. It includes recommendations on ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...